Opinion

Video

Concluding Thoughts on the Treatment of Dry Eye Disease

Key opinion leaders share their final thoughts on advancing treatments of Dry Eye Disease.

This is a video synopsis/summary of a Stakeholder Summit involving:

Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.

Haumschild asks about primary obstacles reducing dry eye disease (DED) treatment effectiveness. Parekh states providers are diagnosing DED, preferred practice guidelines are evolving, and industry innovation continues. However, insurance barriers such as step therapy protocols remain frustrating despite expanding options. This leads to communication breakdowns with patients wrongly ascribing access issues to their provider. He urges payers to demand evidence of efficacy but facilitate access so comprehensive DED care is achievable for every patient subtype. As DED progresses untreated, exponentially costlier specialized treatments become necessary. Early intervention optimizes value.

In concluding key takeaways for stakeholders, Kabiri advocates embracing innovation benefiting large patient subgroups that lowers long-term disease costs. Parekh foresees targeted DED therapies matched to specific deficiencies at the right timepoints with better coverage as the ideal future landscape through continued collaboration across stakeholders to fulfill unmet needs.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.

Related Videos
1 KOL is featured in this series.
1 expert is featured in this series.
5 experts are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo